Verition Fund Management LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Verition Fund Management LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,022 shares of the biopharmaceutical company’s stock, valued at approximately $129,000.

Several other hedge funds also recently modified their holdings of the stock. Trexquant Investment LP lifted its stake in Catalyst Pharmaceuticals by 19.3% in the 2nd quarter. Trexquant Investment LP now owns 86,951 shares of the biopharmaceutical company’s stock valued at $610,000 after purchasing an additional 14,094 shares during the last quarter. Profund Advisors LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $161,000. Virtu Financial LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $1,140,000. Raymond James Financial Services Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 26.9% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 300,013 shares of the biopharmaceutical company’s stock valued at $3,849,000 after purchasing an additional 63,674 shares during the last quarter. Finally, Prudential Financial Inc. lifted its stake in Catalyst Pharmaceuticals by 16.3% in the 3rd quarter. Prudential Financial Inc. now owns 1,492,625 shares of the biopharmaceutical company’s stock valued at $19,149,000 after purchasing an additional 209,580 shares during the last quarter. Institutional investors own 86.66% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 2.7 %

Shares of CPRX stock opened at $14.64 on Friday. The firm has a 50 day moving average price of $16.77 and a two-hundred day moving average price of $15.57. The company has a market capitalization of $1.52 billion, a PE ratio of 24.00 and a beta of 1.16. Catalyst Pharmaceuticals, Inc. has a 12-month low of $6.15 and a 12-month high of $22.11.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CPRX shares. HC Wainwright raised their target price on shares of Catalyst Pharmaceuticals from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, December 21st. Piper Sandler raised their price objective on shares of Catalyst Pharmaceuticals from $20.00 to $21.00 in a research report on Tuesday, February 7th. Finally, Truist Financial raised their price objective on shares of Catalyst Pharmaceuticals from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, January 19th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.63.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.